Predictors of Future Type 2 Diabetes Mellitus in Circassians Minority in Israel
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01311401|
Recruitment Status : Unknown
Verified February 2013 by Osamah Hussein, Ziv Hospital.
Recruitment status was: Recruiting
First Posted : March 9, 2011
Last Update Posted : February 20, 2013
The aim of the present study is:
- The metabolic risk factors that can predict diabetes after 10 years in a Circassians population-based sample of people who were aged 35 years or older and living in Israel.
- To define the incidence of type 2 diabetes mellitus in Circassians minority in Israel.
The hypothesis of the study:
High fasting glucose has the most powerful predictive value for type 2 diabetes mellitus in the future.
The claimed importance of the study:
Finding a powerful risk factor for future diabetes mellitus can contribute to intensifying the preventive measures in a small part of the population, by that to reduce the incidence of new diabetes without increasing the health cost.
|Condition or disease||Intervention/treatment|
|Diabetes Mellitus Type II||Other: NONE intervention|
Research design and methods The present study is a 10 year, nested prospective cohort, population-based survey of the metabolic syndrome risk factors including type 2 diabetes mellitus. The original cross-sectional survey was conducted in two small Circassian villages in north Israel with 4000 inhabitants. The baseline evaluation was performed between 1996 and - 1997. Among the 739 randomly selected men (n=289) and women (n=450 of the 4000 individuals who were aged 35 years or older. Mean age of men was 53.2±11.8 years and of women was 52± years. Mean BMI for men and women was 27.5± and 29.4± Kg/m2, respectively. Plasma glucose level for men and women was mg/dL(22).
The investigators will recruit the same cohort in the proposed study and individuals who were free of diabetes at base line will be included. The number of deceased changed their residence and those who will decline to participate in the follow-up study will be reported.
The protocol was approved by the Ethics Committee of the Ziv hospital and all participants will give an informed consent.
Clinical data. Body mass index (BMI), fasting blood glucose, blood total cholesterol, triglycerides, low density cholesterol (LDL), high density cholesterol (HDL) and blood pressure measurements were done 10 years ago. In the present study, after 8 hours of caloric fast, blood glucose levels will be tested and patients will be asked about known recent diabetes mellitus in the last 10 years or treatment by dietary, hypoglycemic drugs or insulin.
Laboratory data. In the morning, after an overnight caloric fast, venous blood will be sampled for the measurement of plasma concentrations of glucose. The blood levels of glucose will be done by Olympus 640 at ZIV hospital. Diagnosis of diabetes. At baseline and at the 10-year follow-up, the presence of diabetes will be established according to World Health Organization (WHO) criteria (84), i.e., when fasting glucose will be ≥126 mg/dl or when the participants will have a clinical diagnosis of the disease and treatment was ongoing (diet, drugs).
The presence of the disease will be confirmed by reviewing the medical records of their general practitioners. No case of diabetes will be accepted without a validated confirmation.
|Study Type :||Observational|
|Estimated Enrollment :||670 participants|
|Official Title:||Predictors of Future Type 2 Diabetes Mellitus in Circassians Minority in Israel|
|Study Start Date :||October 2009|
|Estimated Primary Completion Date :||July 2014|
Rehania village (Kfar Rehania)
Other: NONE intervention
Kama village (Kfar Kama )
Other: NONE intervention
- New incidences of Type II Diabetes Mellitus in Circassians minority in Israel [ Time Frame: 14 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01311401
|Contact: Osamah Hussein, MD||+972 email@example.com|
|Ziv Medical Center||Recruiting|
|Safed, Israel, 13110|
|Contact: Osamah Hussein, MD firstname.lastname@example.org|
|Principal Investigator: Osamah Hussein, MD|